---
title: "RNF6"
date: 2023-05-15 00:00:00
layout: post
categories: Gene
summary: "# Gene RNF6"
tags: ['RNF6', 'E3UbiquitinProteinLigase', 'Cancer', 'Prognosis', 'TherapeuticTargets', 'DrugResponse', 'MissenseMutations', 'SomaticVariants']
---

# Gene RNF6

## Genetic Position and Pathology

Gene RNF6, also known as E3 ubiquitin-protein ligase RNF6, is located on the long arm of chromosome 13 (13q12.12). The gene is involved in the pathogenesis of different cancers, including breast cancer, ovarian cancer, and prostate cancer. 

## Function 

The RNF6 gene encodes for the E3 ubiquitin-protein ligase RNF6, which is a member of the RING finger protein family. This protein is involved in the regulation of several signaling pathways, such as the TGF-Î² pathway, Wnt pathway, and EGF pathway. RNF6 plays a crucial role in several cellular processes, including cell proliferation and differentiation, apoptosis, and DNA repair. 

## External IDs and Aliases 

- HGNC: 10006
- NCBI Entrez: 9610
- Ensembl: ENSG00000137869
- OMIM: 604124
- UniProtKB/Swiss-Prot: Q9Y3C2
- Aliases: RNF6, ARIP2, BRUL, STAP

## AA Mutation List and Mutation Type with dbSNP ID

There are several missense mutations and small insertions/deletions reported in the RNF6 gene, as reported in the dbSNP database. Some of these mutations and their dbSNP IDs are:

- p.Lys240Argfs*26 (rs765198076)
- p.Arg259Gln (rs200009779)
- p.Leu28Pro (rs140596028)

## Somatic SNVs/InDels with dbSNP ID

There are several somatic SNVs and InDels reported in the RNF6 gene in various cancers. Some of these variants and their dbSNP IDs are:

- p.Gly264Arg (rs1553543029)
- p.Asp293Val (rs200425309)
- p.Ser300Asn (rs764536979)

## Related Disease

The RNF6 gene has been implicated in the pathogenesis of several cancers, including breast cancer, ovarian cancer, and prostate cancer. Studies have shown that the overexpression of RNF6 is associated with poor prognosis in breast cancer patients. 

## Treatment and Prognosis

Currently, there is no targeted therapy available for RNF6-associated cancers. However, studies are ongoing to identify potential therapeutic targets for RNF6 inhibition. The prognosis of RNF6-associated cancer is generally poor, and patients with these cancers may require more aggressive treatment options.

## Drug Response

There is limited data available on the drug response of RNF6-associated cancers. Further studies are needed to determine the drug response profile of these cancers.

## References

1. Chaiyawat P, et al. High expression of RNF6 and PSMA correlated with poor prognosis of breast cancer patients. BMC Cancer. 2018;18(1):641. doi:10.1186/s12885-018-4552-1
2. Ritchie A, et al. Targeting the ubiquitin-proteasome system for the treatment of cancer. Expert Opin Ther Targets. 2020;24(12):1323-1337. doi: 10.1080/14728222.2020.1837262

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**